Summary & Overview
HCPCS Q0511: Pharmacy Supply Fee for Oral Anticancer/Immunosuppressive Drugs
HCPCS Level II code Q0511 designates a pharmacy supply fee for the first prescription in a 30-day period for oral anti-cancer, oral anti-emetic, or immunosuppressive medications. The code captures a dispensing or administrative component tied to specialty oral agents and is used across pharmacy and outpatient settings where these drugs are supplied. Nationally, this code matters because oral specialty therapies are increasingly common, and supply fees affect patients, pharmacy workflows, and payer reimbursement arrangements.
Key payers referenced in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise explanation of the clinical and service context for Q0511, typical sites where it is applied, and which payers commonly cover or process claims that include this supply fee.
The publication provides benchmarks and policy context where available, notes on billing practices tied to first-prescription timing within a 30-day window, and a summary of common modifiers and payer considerations. Data not available in the input is identified where applicable. The goal is to give billing managers, pharmacy administrators, and policy analysts a clear, national-level reference for using HCPCS Level II code Q0511 in outpatient pharmacy dispensing scenarios.
Billing Code Overview
HCPCS Level II code Q0511 describes a pharmacy supply fee for oral anti-cancer, oral anti-emetic, or immunosuppressive drug(s) billed for the first prescription in a 30-day period. This code represents an administrative or dispensing-related charge associated with providing an oral specialty medication rather than the medication itself.
Service Type: Pharmacy dispensing / supply fee
Typical Site of Service: Retail or specialty pharmacy or other outpatient pharmacy settings where oral oncology, anti-emetic, or immunosuppressive agents are dispensed.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female with metastatic breast cancer presents to the oncology clinic after her oncologist prescribes an oral anti-cancer agent to be started immediately. The clinic’s infusion pharmacy dispenses the first 30-day prescription of the oral chemotherapy and assesses patient education, drug–drug interaction screening, and initial counseling on adverse effects and adherence. The pharmacy charges the pharmacy supply fee represented by Q0511 for the first prescription in a 30-day period. Typical workflow steps include: medication reconciliation and verification by the pharmacist, provision of counseling and written instructions, documentation of the dispense in the electronic health record, communication of any necessary monitoring plans to the oncology team, and billing the pharmacy supply fee with the initial outpatient dispense.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when additional pharmacist clinical effort or extensive counseling beyond usual is well documented and billed in support of the supply fee. |
52 | Reduced services |